Just to reiterate the point. Here is a recent survey on MSCs to treat GvHD highlighting the need for a manufacturing solution. That’s where Cymerus comes in. Time for management time to be directed more at deal making and less at directors’ personal finances.
http://www.gvhdhub.com/medical-info...or-the-treatment-of-graft-versus-host-disease
Ann: Notice of General Meeting/Proxy Form, page-98
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 25.0¢ | $5.869K | 22.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29342 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.47pm 11/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |